We treated two BRAF-mutant and one BRAF wild-type melanoma cell lines with the mutant BRAF inhibitor vemurafenib (0.5 μM) and with the HDACis SAHA (1 μM) and valproate (2 mM) alone, or in combination for 48 h (Figure 2). This evidence concerns the gene BRAF and melanoma.